7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
暂无分享,去创建一个
Wei Wang | C. Weigelt | K. Kish | H. Klei | L. Hamann | M. Kirby | A. Fura | T. Harrity | P. Levesque | Lucy Sun | R. Zahler | Aiying Wang | M. Cap | Y. Li | P. Devasthale | Nathan N Morgan | Donald M Egan